Frontlight ResearchEarly access
Taking people in South KoreaNo phase
Studies biomarkers that may predict Alzheimer's in people with inherited mutations
Looks for signs that may predict Alzheimer's disease in adults carrying a gene mutation.
Key facts
- Who runs it
- Washington University School of Medicine
- Where
- Seoul, South KoreaSee the siteAlso in 12 other countries, 25 sites
- Trial code
- Registry title
- Dominantly Inherited Alzheimer Network (DIAN)
- Status
- Recruiting
- People taking part
- 700 people, planned
- Started
- Jan 2009
- Expected to end
- Sept 2031
- Type of study
- Observational, 2 groups
- Record updated
- 5 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults whose parent has Alzheimer's disease caused by a known inherited gene mutation. Most people recruited have no memory problems yet.
- Age
- 18 years or older
- Sex
- Women and men can join
- Disease stage
- No memory problems, or very mild or mild memory problems (CDR score 0 to 1.0). Most new people are adult children with no symptoms, more than 15 years younger than the expected age when symptoms start. People with moderate memory problems can join only with approval from the DIAN Coordinating Center.
- Biomarker or test result
- Is the child of a parent with a known Alzheimer's mutation for ADAD (a dominantly inherited form of Alzheimer's disease). The parent's mutation was shown by symptoms or by a test.
Main reasons for not taking part
- Younger than 18
- An illness, medical or mental, that would get in the way of the visits
- Needs nursing home level care
- Has no one who can act as an informant for the study
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Written informed consent obtained from participant and collateral source prior to any study-related procedures
- Aged 18 (inclusive) or older and the child of an affected individual (clinically or by testing) in a pedigree with a known mutation for ADAD
- Cognitively normal to very mild or mild cognitive impairment (CDR score range 0-1.0). Primary enrollment will focus on the recruitment of asymptomatic adult children who are more than 15 years younger than the estimated age of symptom onset. Enrollment of new participants with moderate cognitive impairment is allowed with the prior approval of the DIAN Coordinating Center
- Has two persons who are not their full-blooded siblings who can serve as collateral sources for the study
- Fluent in a language approved by the DIAN Coordinating Center at about the 6th grade level (international equivalent) or above
Who cannot take part
- Medical or psychiatric illness that would interfere in completing initial and follow-up visits
- Under age 18
- Requires nursing home level care
- Has no one who can serve as a study informant
Where in South Korea
Also in 12 other countries, 25 sites
- Asan Medical CenterSeoul, South KoreaContact: Jee Hoon Roh, MD, PhDTaking people
About the trial
What the trial wants to find out
The purpose of this study is to identify potential biomarkers that may predict the development of Alzheimer's disease in people who carry an Alzheimer's mutation.
The 2 groups in the trial
- 1
Mutation Positive
- 2
Mutation Negative
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Dominantly Inherited Alzheimer Network (DIAN)
- Plain-language title
- Studies biomarkers that may predict Alzheimer's in people with inherited mutationsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Publications
- Investigation of sex differences in mutation carriers of the Dominantly Inherited Alzheimer Network.Alzheimer's & dementia : the journal of the Alzheimer's Association, 2024
- Diffusion Tensor MRI Structural Connectivity and PET Amyloid Burden in Preclinical Autosomal Dominant Alzheimer Disease: The DIAN Cohort.Radiology, 2022
- Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study.The Lancet. Neurology, 2018
- Record updated
- 5 October 2026